Blog

The Kings Fund QMR

What does last year’s NHS spend on pharma look like?

What does last year’s NHS spend on pharma look like?

Reporting by The King’s Fund this year, revealed that total NHS spending on medicines in England rose from around £13 billion in 2010/11 to £17.4 billion in 2016/17. It also revealed that the average reported growth of around 5 per cent a year is outstripping growth in the total NHS budget.

What do these numbers look like?

As specialists in managing and enhancing large and difficult to interpret datasets, we used our next-generation toolkit, RX Analyser, to create a clear, visual interpretation of last year’s NHS pharma spend.

Drilling down to details

When looking at how the health service controls spending on medicines, the King’s Fund reports increased controls on spending and promoting value for money.

A key part of the new guidance is that “low-value medicines (e.g., herbal treatments and some painkillers) and products that are widely available over the counter (e.g., for minor illnesses such as coughs and colds) shouldn’t be routinely prescribed in primary care.”

NHS Medicines Provision

Actionable analytics at your fingertips

Inspiremed provides powerful data analytics to clients in companies across the healthcare sector. We can help you to make analytics simple and can provide specialist help with your prescribing-related questions.

With our data-driven approach that gives robust, pragmatic and accurate real world analysis, you can build your business strategy with confidence, replacing estimates and guess work with proven facts and figures.

Find out more

Are you ready to gain market analytics and valuable insights – and make swift responses to market changes with ease?

To learn more and book your demonstration
info@inspire-med.co.uk
01600 891594

 

“Benefits? The range of views of the data allows for easier business planning. The data being as up to date as possible enables swift response to market changes. And the ease of changing hierarchy allows for easy management reporting and oversight.”

National Sales Manager, UK Pharmaceutical Company

“Rx Analyser is already having a significant impact on our business, allowing our Territory Managers to focus on established CCG accounts and identify practice level successes and others for further development.”

Managing Director, UK Diabetes Healthcare Company

“Working with Inspiremed is a great partnership experience and they make sure they understand your business, the industry that you are in and what you want to achieve in the use of the product.”

National Sales Manager, UK Pharmaceutical Company

“Customers tell us our platform has changed the way they work, that they’ve enhanced the strategies they implement, based on the work they’ve done with the analyser tool and that – bottom line – we’ve helped them to increase their sales. That’s a pretty good result from a chance cup of coffee.”

Andrew Norman and David Warwick, Directors

“Need to analyse the community market? This tool can do that.”

Senior Manager, Global Healthcare Company, 2016

“My favourite feature? The market share data – and territory growth or decline. The RXA tool really allows a company to fine tune their sales strategies and focus on the more profitable accounts. It allows you to target accounts for quick wins and get a good picture of what your competitor’s focuses and successes are.”

National Sales Manager, UK Pharmaceutical Company

Sign up for added insights